SCG-101

N/A

Report date: 2025/12/05 14:02:56

Base Information

Drug NameSCG-101
Drug Alias NameSCG101-V自体T细胞注射液SCG-101VSCG101SCG-101
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionT lymphocyte replacementsHBsAg inhibitors
TargetsHepatitis B Surface Antigens
Therapy Area/IndicationsLiver NeoplasmsBiliary Tract NeoplasmsCarcinoma, Hepatocellular +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSingaporeHong Kong +[4] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesSCG Science (Shanghai) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesSCG Science (Shanghai) Co LtdSCG Cell Therapy Pte Ltd
Inactive CompaniesN/A
Active IndicationsLiver NeoplasmsBiliary Tract NeoplasmsCarcinoma, Hepatocellular +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A